Supplementary materials:

Supplementary Table: Outcome and exposure tables for the outcome (a) IBD (b) UC (c) CD

| **Exposure group** | **Age (years)** | **Number of events** | **Person-years** | **Absolute risk (number of events by 10,000 person years)** | **Median age at onset** |
| --- | --- | --- | --- | --- | --- |
| Exposed to mebendazole before age 5 years | 0-16 | 326 | 2,934,082 | 1.1 | 12.11 |
| Exposed to mebendazole before age 5 years | 16-22 | 382 | 420,974 | 9.1 | 18.69 |
| Exposed to mebendazole between age 5 and 18 years | 0-16 | 278 | 1,433,688 | 1.9 | 12.91 |
| Exposed to mebendazole between age 5 and 18 years | 16-22 | 352 | 457,432 | 7.7 | 18.59 |
| Not exposed to mebendazole before age 18 years | 0-16 | 951 | 11,603,439 | 0.8 | 11.87 |
| Not exposed to mebendazole before age 18 years | 16-22 | 765 | 997,542 | 7.7 | 18.75 |

| **Exposure group** | **Age (years)** | **Number of events** | **Person-years** | **Absolute risk (number of events by 10,000 person years)** | **Median age at onset** |
| --- | --- | --- | --- | --- | --- |
| Exposed to mebendazole before age 5 years | 0-16 | 154 | 2,934,082 | 0.5 | 11.64 |
| Exposed to mebendazole before age 5 years | 16-22 | 202 | 420,974 | 4.8 | 18.93 |
| Exposed to mebendazole between age 5 and 18 years | 0-16 | 143 | 1,433,688 | 1.0 | 12.92 |
| Exposed to mebendazole between age 5 and 18 years | 16-22 | 173 | 457,432 | 3.8 | 18.61 |
| Not exposed to mebendazole before age 18 years | 0-16 | 439 | 11,603,439 | 0.4 | 11.30 |
| Not exposed to mebendazole before age 18 years | 16-22 | 351 | 997,542 | 3.5 | 18.85 |

| **Exposure group** | **Age (years)** | **Number of events** | **Person-years** | **Absolute risk (number of events by 10,000 person years)** | **Median age at onset** |
| --- | --- | --- | --- | --- | --- |
| Exposed to mebendazole before age 5 years | 0-16 | 172 | 2,934,082 | 0.6 | 12.42 |
| Exposed to mebendazole before age 5 years | 16-22 | 180 | 420,974 | 4.3 | 18.43 |
| Exposed to mebendazole between age 5 and 18 years | 0-16 | 135 | 1,433,688 | 0.9 | 12.87 |
| Exposed to mebendazole between age 5 and 18 years | 16-22 | 179 | 457,432 | 3.9 | 18.54 |
| Not exposed to mebendazole before age 18 years | 0-16 | 512 | 11,603,439 | 0.4 | 12.38 |
| Not exposed to mebendazole before age 18 years | 16-22 | 414 | 997,542 | 4.2 | 18.74 |

Supplementary figure: Directed acyclic graph depicting the hypothesized relationship between mebendazole (exposure, green), inflammatory bowel disease (outcome, blue), parental IBD (ancestor of the outcome, blue) and potential confounding variables (red).

